Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Abstract

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects [RAW_REF_TEXT] Ilaria Romito1 na1, [/RAW_REF_TEXT] [RAW_REF_TEXT] Manuela Porru2 na1, [/RAW_REF_TEXT] [RAW_REF_TEXT] Maria Rita Braghini1 na1, [/RAW_REF_TEXT] [RAW_REF_TEXT] Luca Pompili2, [/RAW_REF_TEXT] [RAW_REF_TEXT] Nadia Panera1, [/RAW_REF_TEXT] [RAW_REF_TEXT] Annalisa Crudele1, [/RAW_REF_TEXT] [RAW_REF_TEXT] Daniela Gnani3, [/RAW_REF_TEXT] [RAW_REF_TEXT] Cristiano De Stefanis4, [/RAW_REF_TEXT] [RAW_REF_TEXT] Marco Scarsella4, [/RAW_REF_TEXT] [RAW_REF_TEXT] Silvia Pomella5, [/RAW_REF_TEXT] [RAW_REF_TEXT] Stefano Levi Mortera6, [/RAW_REF_TEXT] [RAW_REF_TEXT] Emmanuel de Billy5, [/RAW_REF_TEXT] [RAW_REF_TEXT] Adrian Libenzio Conti4, [/RAW_REF_TEXT] [RAW_REF_TEXT] Valeria Marzano6, [/RAW_REF_TEXT] [RAW_REF_TEXT] Lorenza Putignani6,7, [/RAW_REF_TEXT] [RAW_REF_TEXT] Manlio Vinciguerra8,9, [/RAW_REF_TEXT] [RAW_REF_TEXT] Clara Balsano10,11, [/RAW_REF_TEXT] [RAW_REF_TEXT] Anna Pastore12, [/RAW_REF_TEXT] [RAW_REF_TEXT] Rossella Rota5, [/RAW_REF_TEXT] [RAW_REF_TEXT] Marco Tartaglia13, [/RAW_REF_TEXT] [RAW_REF_TEXT] Carlo Leonetti2 & [/RAW_REF_TEXT] [RAW_REF_TEXT] Anna Alisi 1 [/RAW_REF_TEXT] Journal of Experimental & Clinical Cancer Research volume 41, Article number: 40 (2022) Cite this article [RAW_REF_TEXT] 134 Accesses [/RAW_REF_TEXT] [RAW_REF_TEXT] 1 Altmetric [/RAW_REF_TEXT] [RAW_REF_TEXT] Metrics details [/RAW_REF_TEXT] The Original Article was published on 16 November 2021 Correction to: J Exp Clin Cancer Res 40, 364 (2021). https://doi.org/10.1186/s13046-021-02154-8 Following publication of the original article [1], the authors identified errors Figs. 3, 4, 5 and 6 specifically: NT Full size image Figure 3d - Percentage of HCC cells in G0/G1, S and G2/M phase of the cell cycle by PI staining and flow cytometry analysis. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects [RAW_REF_TEXT] Ilaria Romito1 na1, Manuela Porru2 na1, Maria Rita Braghini1 na1, Luca Pompili2, Nadia Panera1, Annalisa Crudele1, Daniela Gnani3, Cristiano De Stefanis4, Marco Scarsella4, Silvia Pomella5, Stefano Levi Mortera6, Emmanuel de Billy5, Adrian Libenzio Conti4, Valeria Marzano6, Lorenza Putignani6,7, Manlio Vinciguerra8,9, Clara Balsano10,11, Anna Pastore12, Rossella Rota5, Marco Tartaglia13, Carlo Leonetti2 & Anna Alisi 1 [/RAW_REF_TEXT] Journal of Experimental & Clinical Cancer Research volume 41, Article number: 40 (2022) Cite this article [RAW_REF_TEXT] 134 Accesses 1 Altmetric Metrics details